Scully v. AltaThera Pharmaceuticals LLC

2025 IL App (1st) 242078-U
Appellate Court of Illinois·Decided June 30, 2025·No. 1-24-2078·Unpublished

Opinion

2025 IL App (1st) 242078-U No. 1-24-2078

Order filed June 30, 2025.

First Division

NOTICE: This order was filed under Supreme Court Rule 23 and is not precedent except in the limited circumstances allowed under Rule 23(e)(1).

IN THE

APPELLATE COURT OF ILLINOIS FIRST DISTRICT

JAMES SCULLY, ) Appeal from the ) Circuit Court of

Plaintiff-Appellant, ) Cook County.

)

v. ) No. 22 L 11440 )

ALTATHERA PHARMACEUTICALS LLC, ) The Honorable ) Catherine A. Schneider, Defendant-Appellee. ) Judge Presiding.

JUSTICE LAVIN delivered the judgment of the court.

Presiding Justice Fitzgerald Smith and Justice Pucinski concurred in the judgment.

ORDER

¶1 Held: Appeal dismissed for lack of jurisdiction where the circuit court’s dismissal of two counts in plaintiff’s second amended complaint did not constitute a final judgment.

¶2 Plaintiff James Scully filed suit against defendant AltaThera, setting forth a number of counts seeking relief for violations under the Illinois Wage Payment and Collection Act (Wage Act) (820 ILCS 115/1 et seq. (West 2022)), breach of contract, and quantum meruit. The circuit court eventually dismissed the Wage Act and breach of contract counts with prejudice, but allowed

Scully to proceed on the quantum meruit counts. Scully filed an amended complaint only alleging the quantum meruit counts and later sought a finding, pursuant to Illinois Supreme Court Rule 304(a) (eff. Mar. 8, 2016), that the dismissal of the Wage Act and breach of contract counts was a final, appealable judgment. The court granted Scully’s request, and he appealed.

¶3 AltaThera now asserts the lower court’s Rule 304(a) finding was improper because the dismissal of Scully’s Wage Act and breach of contract counts was not a final judgment, since those counts contained the same operative facts as Scully’s quantum meruit counts that are still pending in the court below. We agree. For the following reasons, we dismiss the appeal for lack of jurisdiction.

¶4 I. BACKGROUND

¶5 On December 27, 2024, Scully filed a complaint alleging that AtlaThera failed to fully compensate him for work performed from December 1, 2018, through October 10, 2021, when he worked as AltaThera’s full-time Chief Financial Officer (CFO), a fact that AtlaThera later denied in its answer. AltaThera successfully moved to dismiss the complaint pursuant to section 2-615 of the Code. The court dismissed the complaint without prejudice and granted Scully leave to amend his pleadings. Scully filed a first amended complaint, but then moved for leave to file a second amended complaint, which the court allowed.

¶6 Scully’s second amended complaint set forth five counts, all seeking compensation for his alleged work as AltaThera’s CFO: (1) compensation owed under the Wage Act; (2) breach of contract; (3) quantum meruit relief for compensation excluding equity; (4) quantum meruit relief for an equity stake; and (5) reimbursement for the employer share of payroll taxes paid by Scully.

¶7 Scully alleged that he worked as AltaThera’s full-time CFO from about December 1, 2018, to October 10, 2021. He worked for “at least” 40 hours a week and “usually” more than 40 hours. In early January 2019, he and AltaThera’s Chief Executive Officer entered into a verbal agreement regarding compensation by AltaThera for Scully’s work, effective as of December 1, 2018. Their agreement called for Scully to bill AltaThera for 32 hours of work a week in exchange for $25,000 a month, which equated to an hourly rate of about $180. Scully alleged that “[t]his verbal agreement did not address the situation where [he] worked more than 32 hours per week.” Nonetheless, according to Scully, AltaThera knowingly allowed him to work 40 or more hours a week and “accepted all of the work Scully performed.” From September 2019 through February 2021, AltaThera allegedly initiated an “austerity program” whereby it paid Scully for less than 32 hours a week, regardless of how many hours Scully worked. Scully also claimed that, from March 2021 through October 2021, AltaThera paid him a temporary rate of $18,750 a month while negotiating an employment contract with him. Scully alleged that he resigned from his position as “full-time CFO of AltaThera,” effective October 11, 2021.

¶8 In his Wage Act count, Scully alleged that, as an “employee” of AltaThera under the Wage Act, he was owed $327,047.69 in wages for the unpaid work he performed from December 2018 through October 10, 2021, i.e., the hours of work exceeding 32 hours a week. He also alleged he was entitled to compensation for the reductions in pay AltaThera made during the alleged “austerity program” and employment contract negotiations. In his breach of contract count, Scully alleged that he and AltaThera entered into a contract, which AltaThera breached by not paying him the agreed hourly rate of $180.29 for each hour he worked.

¶9 AltaThera moved to dismiss Scully’s second amended complaint pursuant to section 2-615 of the Code. On December 8, 2023, after briefing on the motion, the circuit court granted AltaThera’s dismissal motion. The court dismissed with prejudice Scully’s Wage Act, breach of contract, and tax counts. It found in part that Scully failed to allege that AltaThera agreed to pay him for more than 32 hours of work a week. The court also dismissed Scully’s two quantum meruit counts without prejudice, allowing Scully leave to amend them.

¶ 10 On January 8, 2024, Scully moved to reconsider the court’s dismissal. On May 2, 2024, the court denied the motion as to Scully’s Wage Act, breach of contract, and tax counts, but granted the motion as to his quantum meruit counts.

¶ 11 On May 9, 2024, Scully filed a third amended complaint, restating his two quantum meruit counts but omitting all other counts alleged in the second amended complaint. He again stated the facts in his second amended complaint regarding his work provided as a “full-time CFO” for AltaThera from December 1, 2018, through October 10, 2021. For his first quantum meruit count, Scully alleged he was entitled to compensation for “non-gratuitously performed services” as CFO to AltaThera’s benefit, which AltaThera accepted. He sought $326,952 in damages, calculated by multiplying a $180 hourly rate by the amount of hours worked without compensation. For his second quantum meruit count, Scully alleged that he was also entitled to $406,233, the alleged fair cash value of an equity stake in AltaThera that he claimed was owed to him.

¶ 12 On May 31, 2024, while Scully’s third amended complaint was pending, Scully filed a notice of appeal. We dismissed the appeal for lack of jurisdiction. Scully v. AltaThera Pharmaceuticals, No. 1-24-1182 (Aug. 9, 2024) (dispositional order dismissing the appeal for lack

of this court’s jurisdiction). In the meantime, AltaThera had filed an answer to Scully’s third amended complaint.

¶ 13 On July 30, 2024, Scully moved for a Rule 304(a) finding there was no just reason for delaying either enforcement or appeal or both of the circuit court’s dismissal of his second amended complaint’s Wage Act and breach of contract counts. AltaThera filed a response, arguing that the court’s dismissal wasn’t a final judgment as to a definite and separate part of litigation, as the dismissed counts from Scully’s second amended complaint shared the same operative facts as the remaining quantum meruit counts.

¶ 14 On September 18, 2024, the circuit court granted Scully’s request for a Rule 304(a) finding, and he appealed.

¶ 15 II. ANALYSIS

Free access — add to your briefcase to read the full text and ask questions with AI

Scully v. AltaThera Pharmaceuticals LLC, 2025 IL App (1st) 242078-U (Ill. Ct. App. 2025).

2025 IL App (1st) 242078-U (Scully v. AltaThera Pharmaceuticals LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Cano v. Cruz
2026 IL App (1st) 250172-U (Appellate Court of Illinois, 2026)